Assertio Holdings, Inc. Overview
Pro stress-test →Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients with a robust portfolio of branded prescription neurology, inflammation, pain and oncology medications. In the volatile world of specialty pharmaceuticals where generic competition and regulatory headwinds often erode margins, Assertio has emerged as a rare success story with strategic transformation, earnings outperformance, and a fortress-like balance sheet.
Strategic Profile
Pro stress-test →The company has pivoted from a cost-cutting exercise to a growth-oriented strategy by exiting non-core assets and doubling down on high-margin products. Key products Rolvedon and Sympazan saw sequential sales increases of 20% and 18.5% respectively in Q2 2025.
Competitive Landscape
Pro stress-test →As a specialty pharmaceutical company in neurology, hospital, and pain and inflammation markets, Assertio competes against larger pharma companies like Pfizer, AbbVie, and smaller specialty players including Collegium Pharmaceuticals, Akebia Therapeutics, and Ironwood Pharmaceuticals. The company differentiates through a focused portfolio of branded generics targeting high-margin chronic condition indications.
Industry Context
Assertio Holdings, Inc. operates in Specialty Pharmaceuticals.
Key facts
Founded: 1995 · Headquarters: Lake Forest, Illinois · Revenue: $28.8M · Market cap: $79.4M